Protocol for the MPTP mouse model of Parkinson's disease.
about
Chronic exposure to corticosterone enhances the neuroinflammatory and neurotoxic responses to methamphetamineModeling Parkinson's disease in the common marmoset (Callithrix jacchus): overview of models, methods, and animal careEvaluation of Models of Parkinson's DiseaseUncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repairPioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammationNovel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's diseaseSulforaphane protects against rotenone-induced neurotoxicity in vivo: Involvement of the mTOR, Nrf2, and autophagy pathways.Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's diseaseParkinson's disease: animal models and dopaminergic cell vulnerabilityThe sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemiaGene-environment interactions: key to unraveling the mystery of Parkinson's diseaseSuppression of neuroinflammation by astrocytic dopamine D2 receptors via αB-crystallinThe high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's diseaseA Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotectionDopaminergic Neurodegeneration in the Mouse Is Associated with Decrease of Viscoelasticity of Substantia Nigra Tissue.Identification of Neurexophilin 3 as a Novel Supportive Factor for Survival of Induced Pluripotent Stem Cell-Derived Dopaminergic ProgenitorsRecombinant human mitochondrial transcription factor A stimulates mitochondrial biogenesis and ATP synthesis, improves motor function after MPTP, reduces oxidative stress and increases survival after endotoxinMurine motor and behavior functional evaluations for acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication.Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson diseaseLack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.A translational approach to capture gait signatures of neurological disorders in mice and humans.Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease.Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neuronsCerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinson's disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS).Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo.Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease.Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease modelEffects of adenosine receptor antagonists in MPTP mouse model of Parkinson's disease: mitochondrial DNA integrity.Hydrocortisone-induced parkin prevents dopaminergic cell death via CREB pathway in Parkinson's disease modelAdenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's diseaseFibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's diseaseSex differences in motor behavior in the MPTP mouse model of Parkinson's disease.Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease.The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's diseaseGene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease.Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's diseaseCART peptide is a potential endogenous antioxidant and preferentially localized in mitochondria.Evidence of oligodendrogliosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism.Discovery of a neuroprotective chemical, (S)-N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(-)-P7C3-S243], with improved druglike properties.Regional characterization of energy metabolism in the brain of normal and MPTP-intoxicated mice using new markers of glucose and phosphate transport.
P2860
Q23916279-0533676B-E2AF-4B68-9C91-4CBF7BBEDA8AQ26772285-3D62F741-DE7E-4B40-88ED-EA46C7486FF6Q26772843-DE79718D-6BF1-4C7A-8BFE-6A1E5AFE46C0Q26865502-1B006C85-7546-4917-919E-471FD5BADF04Q27301100-343801A9-6759-44D0-9202-1FFF4E00C5C4Q27301283-614A65E7-87ED-484F-872B-A5CC5A00543EQ27314642-37D387A7-7481-4941-A22A-84DC2300A86FQ28074143-7DDE3FA9-CAD4-4428-8AF3-2E6EDB3010F4Q28080503-C550571B-A4E1-4C42-A4FE-87C60F0E618EQ28255782-BF88CFC8-DA29-42F0-90D1-7636C1F169EFQ28388674-EB8A4A60-C0BD-420F-9E04-3C5A265FE2B8Q28510018-E621A796-0A87-4044-B8DE-F813CBD94DF7Q28543195-88AAF1E4-EEA6-4F96-B711-9689217B5CA6Q28589470-6D68F26A-6981-4F5B-A86B-FAFB52E82CEDQ30375763-73CC4ECA-4BE1-498E-AA37-045D3FBE5CE6Q30377980-41723BD2-4957-4C1F-A5B4-52B87243A00CQ30429165-7CE75720-A228-465C-8801-4463FCDDFB0DQ30519556-770C18F0-7A7A-45F1-9CD9-6A832D7A978CQ30525849-30468E06-ADFA-4C5B-90E2-160974FC627DQ30658867-FB051F71-6CBD-432E-9916-6AAB1F28BC0CQ30855500-2F72EEAF-0CAF-483E-AD2C-8476D58A8F6BQ31109638-7E4936B2-52B3-480F-B017-F935BF772928Q33442821-EFA451F3-C890-41F9-896D-954E2BC53439Q33515197-79930B58-2C4A-460C-8845-E1B384E7D368Q33557852-4B2DF9EA-631B-4738-8A4E-734846AD14D6Q33602136-6813BD1C-B41D-4C0C-879B-889F41AEC961Q33608424-44988ACD-131C-4963-B675-CF5B35ED2824Q33645993-E1276051-7635-46D3-A4D0-055CE614882FQ33674504-3E434391-AC5A-4D5D-81CC-1DF12679A76FQ33811654-F45D7DD8-8DB5-47E9-95FF-B8287B1E2EAAQ33829887-733B9EA3-8827-493B-B423-99D9C2FBF0F9Q33835301-E9B62786-FB85-48AB-9D9F-C6183DBE900DQ33843073-92F85789-F8C3-43DF-B03E-59E6EC584CAEQ33850971-F0EB3A56-AA90-42B0-95FD-6EA83EA6ED0CQ33872463-AC4FBBE2-1121-4326-9BA1-227B53471446Q33892744-DEB2DC09-68F0-4075-9932-8DCAAC160430Q34123653-384D369D-46BF-417E-89F7-7FE056209E99Q34207470-ACBF9442-363C-4D54-99A1-82866A77CC69Q34389592-BB7E8515-E6CB-42F9-8B99-7106066AF1ACQ34437354-8BF824FF-F7AA-4557-8F53-58E3C20ADC1A
P2860
Protocol for the MPTP mouse model of Parkinson's disease.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Protocol for the MPTP mouse model of Parkinson's disease.
@ast
Protocol for the MPTP mouse model of Parkinson's disease.
@en
Protocol for the MPTP mouse model of Parkinson's disease.
@nl
type
label
Protocol for the MPTP mouse model of Parkinson's disease.
@ast
Protocol for the MPTP mouse model of Parkinson's disease.
@en
Protocol for the MPTP mouse model of Parkinson's disease.
@nl
prefLabel
Protocol for the MPTP mouse model of Parkinson's disease.
@ast
Protocol for the MPTP mouse model of Parkinson's disease.
@en
Protocol for the MPTP mouse model of Parkinson's disease.
@nl
P356
P1433
P1476
Protocol for the MPTP mouse model of Parkinson's disease.
@en
P2888
P304
P356
10.1038/NPROT.2006.342
P577
2007-01-01T00:00:00Z
P5875
P6179
1046349847